



Final Appraisal Recommendation

Advice No: 2615 – September 2015

**Lisdexamfetamine dimesylate (Elvanse Adult[®]▼) 30 mg, 50 mg
and 70 mg hard capsules**

Submission by Shire Pharmaceuticals Ltd

Recommendation of AWMSG

Lisdexamfetamine dimesylate (Elvanse Adult[®]▼) is recommended as an option for use within NHS Wales as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (ADHD) in adults.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 2534), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue	Shire Pharmaceuticals Ltd
Date of first issue	September 2015
Last reviewed	March 2019

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 2615:
Lisdexamfetamine dimesylate (Elvanse Adult[®]▼) 30 mg, 50 mg and 70 mg hard capsules.
September 2015.